Vanda Pharmaceuticals | VNDA - Trade Creditors


Vanda Pharmaceuticals reported $39.09M in Trade Creditors for its fiscal quarter ending in December of 2024.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 10.9M 10.84M Dec/2025
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Akebia Therapeutics USD 21.18M 11.1M Dec/2025
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Anika Therapeutics USD 6.34M 298K Mar/2026
Arrowhead Research USD 32.94M 15.26M Dec/2025
AstraZeneca USD 22.51B 2.78B Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Esperion Therapeutics USD 65.07M 12.44M Dec/2025
Halozyme Therapeutics USD 20.9M 5.54M Dec/2025
Heron Therapeutics USD 8.99M 3.02M Dec/2025
Insmed USD 79.91M 316K Dec/2025
J&J USD 10.46B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 3.08M 714K Dec/2025
Ligand Pharmaceuticals USD 3.24M 24.52M Dec/2025
Merck USD 3.86B 541M Mar/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Moderna USD 161M 156M Mar/2026
Novartis USD 4.46B 99M Dec/2025
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Puma Biotechnology USD 6.39M 962K Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Takeda JPY 467.59B 28.61B Dec/2025
Teva Pharmaceutical Industries USD 2.6B 65M Mar/2026
Ultragenyx Pharmaceutical USD 31M 9.57M Dec/2025
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Veracyte USD 4.59M 916K Dec/2025